Patents by Inventor Stefan Woll

Stefan Woll has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTIBODIES AGAINST CLAUDIN 18.2 USEFUL IN CANCER DIAGNOSIS
    Publication number: 20240309108
    Abstract: The invention relates to antibodies directed against an epitope located within the C-terminal portion of CLDN18.2 which are useful, for example, in diagnosing cancer and/or in determining whether cancer cells express CLDN18.2.
    Type: Application
    Filed: April 2, 2024
    Publication date: September 19, 2024
    Inventors: Ugur Sahin, Ozlem Tureci, Rita Mitnacht-Kraus, Stefan Woll
  • ANTIBODIES USEFUL IN CANCER DIAGNOSIS
    Publication number: 20240209079
    Abstract: The invention relates to antibodies directed against an epitope located within the C-terminal portion of CLDN6 which are useful, for example, in diagnosing cancer and/or in determining whether cancer cells express CLDN6.
    Type: Application
    Filed: January 26, 2024
    Publication date: June 27, 2024
    Inventors: Rita MITNACHT-KRAUS, Stefan WÖLL, Korden WALTER, Özlem TÜRECI, Ugur SAHIN
  • Antibodies against claudin 18.2 useful in cancer diagnosis
    Patent number: 11976130
    Abstract: The invention relates to antibodies directed against an epitope located within the C-terminal portion of CLDN18.2 which are useful, for example, in diagnosing cancer and/or in determining whether cancer cells express CLDN18.2.
    Type: Grant
    Filed: July 17, 2018
    Date of Patent: May 7, 2024
    Assignees: Astellas Pharma Inc., TRON—Translationale Onkologie an der Universitätsmedizin der Johannes
    Inventors: Ugur Sahin, Ozlem Tureci, Rita Mitnacht-Kraus, Stefan Woll
  • ANTIBODIES FOR TREATMENT OF CANCER EXPRESSING CLAUDIN 6
    Publication number: 20240101703
    Abstract: The present invention provides antibodies useful as therapeutics for treating and/or preventing diseases associated with cells expressing CLDN6, including tumor-related diseases such as ovarian cancer, lung cancer, gastric cancer, breast cancer, hepatic cancer, pancreatic cancer, skin cancer, malignant melanoma, head and neck cancer, sarcoma bile duct cancer, cancer of the urinary bladder, kidney cancer, colon cancer, placental choriocarcinoma, cervical cancer, testicular cancer, and uterine cancer.
    Type: Application
    Filed: November 27, 2023
    Publication date: March 28, 2024
    Inventors: Ugur Sahin, Özlem Türeci, Michael Koslowski, Korden Walter, Stefan Woll, Maria Kreuzberg, Bernd Hubner, Michael Erdeljan, Michael Weichel
  • COMBINATION THERAPY INVOLVING ANTIBODIES AGAINST CLAUDIN 18.2 FOR TREATMENT OF CANCER
    Publication number: 20240091312
    Abstract: The present invention provides a combination therapy for effectively treating and/or preventing diseases associated with cells expressing CLDN18.2, including cancer diseases such as pancreatic cancer and metastases thereof.
    Type: Application
    Filed: August 24, 2023
    Publication date: March 21, 2024
    Inventors: Ugur Sahin, Özlem Türeci, Rita Mitnacht-Kraus, Stefan Wöll, Stefan Jacobs, Cornelia Heinz
  • ANTIBODIES SPECIFIC FOR CLAUDIN 6 (CLDN6)
    Publication number: 20240092896
    Abstract: The present invention provides antibodies useful as therapeutics for treating and/or preventing diseases associated with cells expressing Claudin-6 (CLDN6), including tumor-related diseases such as ovarian cancer, lung cancer, gastric cancer, breast cancer, hepatic cancer, pancreatic cancer, skin cancer, malignant melanoma, head and neck cancer, sarcoma, bile duct cancer, cancer of the urinary bladder, kidney cancer, colon cancer, placental choriocarcinoma, cervical cancer, testicular cancer, and uterine cancer.
    Type: Application
    Filed: November 27, 2023
    Publication date: March 21, 2024
    Inventors: Ugur Sahin, Özlem Türeci, Michael Koslowski, Korden Walter, Stefan Woll, Maria Kreuzberg, Bernd Hubner, Michael Erdeljan
  • Antibodies useful in cancer diagnosis
    Patent number: 11919951
    Abstract: The invention relates to antibodies directed against an epitope located within the C-terminal portion of CLDN6 which are useful, for example, in diagnosing cancer and/or in determining whether cancer cells express CLDN6.
    Type: Grant
    Filed: February 7, 2022
    Date of Patent: March 5, 2024
    Assignees: Astellas Pharma Inc., TRON-Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg-Universität Mainz
    Inventors: Rita Mitnacht-Kraus, Stefan Wöll, Korden Walter, Özlem Türeci, Ugur Sahin
  • Antibodies for treatment of cancer expressing claudin 6
    Patent number: 11859008
    Abstract: The present invention provides antibodies useful as therapeutics for treating and/or preventing diseases associated with cells expressing CLDN6, including tumor-related diseases such as ovarian cancer, lung cancer, gastric cancer, breast cancer, hepatic cancer, pancreatic cancer, skin cancer, malignant melanoma, head and neck cancer, sarcoma bile duct cancer, cancer of the urinary bladder, kidney cancer, colon cancer, placental choriocarcinoma, cervical cancer, testicular cancer, and uterine cancer.
    Type: Grant
    Filed: December 30, 2020
    Date of Patent: January 2, 2024
    Assignees: Ganymed Pharmaceuticals GmbH, Johannes Gutenberg-Universität Mainz
    Inventors: Ugur Sahin, Ozlem Tureci, Michael Koslowski, Korden Walter, Stefan Woll, Maria Kreuzberg, Bernd Hubner, Michael Erdeljan, Michael Weichel
  • Antibodies specific for claudin 6 (CLDN6)
    Patent number: 11858988
    Abstract: The present invention provides antibodies useful as therapeutics for treating and/or preventing diseases associated with cells expressing Claudin-6 (CLDN6), including tumor-related diseases such as ovarian cancer, lung cancer, gastric cancer, breast cancer, hepatic cancer, pancreatic cancer, skin cancer, malignant melanoma, head and neck cancer, sarcoma, bile duct cancer, cancer of the urinary bladder, kidney cancer, colon cancer, placental choriocarcinoma, cervical cancer, testicular cancer, and uterine cancer.
    Type: Grant
    Filed: July 7, 2020
    Date of Patent: January 2, 2024
    Assignees: Ganymed Pharmaceuticals GmbH, Johannes Gutenberg-Universität Mainz
    Inventors: Ugur Sahin, Özlem Türeci, Michael Koslowski, Korden Walter, Stefan Woll, Maria Kreuzberg, Bernd Hubner, Michael Erdeljan
  • Combination therapy involving antibodies against claudin 18.2 for treatment of metastatic pancreatic adenocarcinoma
    Patent number: 11826402
    Abstract: The present invention provides a combination therapy for effectively treating and/or preventing diseases associated with cells expressing CLDN18.2, including cancer diseases such as pancreatic cancer and metastases thereof.
    Type: Grant
    Filed: October 8, 2020
    Date of Patent: November 28, 2023
    Assignees: Astellas Pharma Inc., TRON-Translationale Onkologie an der Universitatsm
    Inventors: Ugur Sahin, Ozlem Tureci, Rita Mitnacht-Kraus, Stefan Woll, Stefan Jacobs, Cornelia Heinz
  • METHODS AND COMPOSITIONS FOR DIAGNOSIS AND TREATMENT OF CANCER
    Publication number: 20230193261
    Abstract: The present invention relates to the identification of nucleic acid and amino acid sequences that are characteristic of tumor tissues such as ovarian tumor and lung tumor tissues and which represent targets for therapy or diagnosis of tumor diseases in a subject.
    Type: Application
    Filed: August 24, 2022
    Publication date: June 22, 2023
    Inventors: Ugur Sahin, Özlem Tureci, Michael Koslowski, Gerd Helftenbein, Korden Walter, Stefan Woll, Gabriela-Elena Oprea
  • Methods and compositions for diagnosis and treatment of cancer
    Patent number: 11473085
    Abstract: The present invention relates to the identification of nucleic acid and amino acid sequences that are characteristic of tumor tissues such as ovarian tumor and lung tumor tissues and which represent targets for therapy or diagnosis of tumor diseases in a subject.
    Type: Grant
    Filed: February 13, 2019
    Date of Patent: October 18, 2022
    Assignees: GANYMED PHARMACEUTICALS GMBH, JOHANNES GUTENBERG-UNIVERSITAT MAINZ
    Inventors: Ugur Sahin, Özlem Tureci, Michael Koslowski, Gerd Helftenbein, Korden Walter, Stefan Woll, Gabriela-Elena Oprea
  • ANTIBODIES USEFUL IN CANCER DIAGNOSIS
    Publication number: 20220162302
    Abstract: The invention relates to antibodies directed against an epitope located within the C-terminal portion of CLDN6 which are useful, for example, in diagnosing cancer and/or in determining whether cancer cells express CLDN6.
    Type: Application
    Filed: February 7, 2022
    Publication date: May 26, 2022
    Inventors: Rita MITNACHT-KRAUS, Stefan WÖLL, Korden WALTER, Özlem TÜRECI, Ugur SAHIN
  • Antibodies useful in cancer diagnosis
    Patent number: 11279757
    Abstract: The invention relates to antibodies directed against an epitope located within the C-terminal portion of CLDN6 which are useful, for example, in diagnosing cancer and/or in determining whether cancer cells express CLDN6.
    Type: Grant
    Filed: September 5, 2018
    Date of Patent: March 22, 2022
    Assignees: Astellas Pharma Inc., TRON—Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg-Universität Mainz Gemeinnützige Gmbh
    Inventors: Rita Mitnacht-Kraus, Stefan Wöll, Korden Walter, Özlem Türeci, Ugur Sahin
  • ANTIBODIES FOR TREATMENT OF CANCER EXPRESSING CLAUDIN 6
    Publication number: 20210179730
    Abstract: The present invention provides antibodies useful as therapeutics for treating and/or preventing diseases associated with cells expressing CLDN6, including tumor-related diseases such as ovarian cancer, lung cancer, gastric cancer, breast cancer, hepatic cancer, pancreatic cancer, skin cancer, malignant melanoma, head and neck cancer, sarcoma bile duct cancer, cancer of the urinary bladder, kidney cancer, colon cancer, placental choriocarcinoma, cervical cancer, testicular cancer, and uterine cancer.
    Type: Application
    Filed: December 30, 2020
    Publication date: June 17, 2021
    Inventors: Ugur Sahin, Ozlem Tureci, Michael Koslowski, Korden Walter, Stefan Woll, Maria Kreuzberg, Bernd Hubner, Michael Erdeljan, Michael Weichel
  • Combination therapy involving antibodies against claudin 18.2 for treatment of pancreatic cancer
    Patent number: 10946069
    Abstract: The present invention provides a combination therapy for effectively treating and/or preventing diseases associated with cells expressing CLDN18.2, including cancer diseases such as pancreatic cancer and metastases thereof.
    Type: Grant
    Filed: May 2, 2019
    Date of Patent: March 16, 2021
    Assignees: Astellas Pharma Inc., TRON-Translationale Onkologie an der Universitatsmedizin der Johannes Gutenberg-Universitat Mainz
    Inventors: Ugur Sahin, Ozlem Tureci, Rita Mitnacht-Kraus, Stefan Woll, Stefan Jacobs, Cornelia Heinz
  • Antibodies for treatment of cancer expressing claudin 6
    Patent number: 10919974
    Abstract: The present invention provides antibodies useful as therapeutics for treating and/or preventing diseases associated with cells expressing CLDN6, including tumor-related diseases such as ovarian cancer, lung cancer, gastric cancer, breast cancer, hepatic cancer, pancreatic cancer, skin cancer, malignant melanoma, head and neck cancer, sarcoma bile duct cancer, cancer of the urinary bladder, kidney cancer, colon cancer, placental choriocarcinoma, cervical cancer, testicular cancer, and uterine cancer.
    Type: Grant
    Filed: July 5, 2018
    Date of Patent: February 16, 2021
    Assignees: Ganymed Pharmaceuticals GmbH, Johannes Gutenberg-Universitat Mainz
    Inventors: Ugur Sahin, Ozlem Tureci, Michael Koslowski, Korden Walter, Stefan Woll, Maria Kreuzberg, Bernd Hubner, Michael Erdeljan, Michael Weichel
  • COMBINATION THERAPY INVOLVING ANTIBODIES AGAINST CLAUDIN 18.2 FOR TREATMENT OF CANCER
    Publication number: 20210023177
    Abstract: The present invention provides a combination therapy for effectively treating and/or preventing diseases associated with cells expressing CLDN18.2, including cancer diseases such as pancreatic cancer and metastases thereof.
    Type: Application
    Filed: October 8, 2020
    Publication date: January 28, 2021
    Inventors: Ugur Sahin, Ozlem Tureci, Rita Mitnacht-Kraus, Stefan Woll, Stefan Jacobs, Cornelia Heinz
  • ANTIBODIES SPECIFIC FOR CLAUDIN 6 (CLDN6)
    Publication number: 20200339677
    Abstract: The present invention provides antibodies useful as therapeutics for treating and/or preventing diseases associated with cells expressing Claudin-6 (CLDN6), including tumor-related diseases such as ovarian cancer, lung cancer, gastric cancer, breast cancer, hepatic cancer, pancreatic cancer, skin cancer, malignant melanoma, head and neck cancer, sarcoma, bile duct cancer, cancer of the urinary bladder, kidney cancer, colon cancer, placental choriocarcinoma, cervical cancer, testicular cancer, and uterine cancer.
    Type: Application
    Filed: July 7, 2020
    Publication date: October 29, 2020
    Inventors: Ugur Sahin, Özlem Türeci, Michael Koslowski, Korden Walter, Stefan Woll, Maria Kreuzberg, Bernd Hubner, Michael Erdeljan
  • Antibodies specific for claudin 6 (CLDN6)
    Patent number: 10745477
    Abstract: The present invention provides antibodies useful as therapeutics for treating and/or preventing diseases associated with cells expressing Claudin-6 (CLDN6), including tumor-related diseases such as ovarian cancer, lung cancer, gastric cancer, breast cancer, hepatic cancer, pancreatic cancer, skin cancer, malignant melanoma, head and neck cancer, sarcoma, bile duct cancer, cancer of the urinary bladder, kidney cancer, colon cancer, placental choriocarcinoma, cervical cancer, testicular cancer, and uterine cancer.
    Type: Grant
    Filed: January 31, 2018
    Date of Patent: August 18, 2020
    Assignees: Ganymed Pharmaceuticals GmbH, Johannes Gutenberg-Universitat Mainz
    Inventors: Ugur Sahin, Özlem Türeci, Michael Koslowski, Korden Walter, Stefan Woll, Maria Kreuzberg, Bernd Hubner, Michael Erdeljan